The crucial role of ICOS for anti-tumor response elicited by CTLA-4-directed ICB renders ICOS as a potential biomarker to predict CTLA-4-directed ICB response and further for the stratification of patients who may benefit from immunotherapeutic ICOS-directed treatment. Here, CTLA4 is linked to neoplasm.